Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor combination therapies in relapsed/refractory DLBCL
NCT04607772Phase 2Withdrawn
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Nov 2020
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in diffuse large B-cell lymphoma (DLBCL), sponsored by Karyopharm Therapeutics Inc.. Planned start Nov 2020; status: withdrawn.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04607772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04607772.